Literature DB >> 25916685

Feline intestinal mast cell tumours: clinicopathological characterisation and KIT mutation analysis.

Silvia Sabattini1, Mery Giantin2, Adele Barbanera1, Lara Zorro Shahidian2, Mauro Dacasto2, Vanessa Zancanella2, Daniela Prata3, Eleonora Trivigno4, Giuliano Bettini5.   

Abstract

OBJECTIVES: Feline intestinal mast cell tumours (FIMCTs) are rare and reportedly characterised by poor differentiation, aggressive biological behaviour and lack of reliable therapeutic aids. KIT proto-oncogene-activating mutations have never been investigated in these tumours. This study describes the main clinicopathological and microscopic features observed in 17 FIMCTs.
METHODS: Tumour degree of differentiation, proliferative activity, Kit protein expression and KIT mutations were evaluated and correlated with survival to assess their prognostic relevance.
RESULTS: Ten tumours were located in the small intestine, two in the ileocaecocolic junction, and five in the large intestine. Survival times ranged from 3-538 days. Fifteen tumours were evaluated histologically, and there were six well-differentiated, six moderately differentiated and three poorly differentiated FIMCTs. The last showed a medium-to-large deposition of collagen tissue (P <0.001), and significantly higher mitotic and Ki67 indexes compared with more differentiated tumours (P = 0.011). On survival analysis, tumour degree of differentiation (P <0.001) and a mitotic index >2 (P = 0.022) were significantly associated with decreased survival times. Twelve cases showed Kit protein immunoexpression. The Kit pattern was membranous in five cases (33.3%), focal paranuclear in five (33.3%) and diffuse cytoplasmic in two (13.3%). Cytoplasmic Kit patterns were associated with a lesser differentiation (P = 0.015). Mutation analysis was successfully performed on 12 primary tumours and four lymph node metastases; however, no encoding mutation was detected. CONCLUSIONS AND RELEVANCE: Contrary to reports in the literature, FIMCTs seem to have an extremely variable biological behaviour. We propose a classification based on tumour degree of differentiation and proliferative activity. These findings need to be confirmed in larger series, and exploration of further genomic regions of KIT is warranted to clarify its role in the development and progression of these neoplasms. © ISFM and AAFP 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25916685     DOI: 10.1177/1098612X15581205

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  5 in total

1.  Evaluation of Ki-67 expression in feline non-ocular melanocytic tumours.

Authors:  Silvia Sabattini; Andrea Renzi; Francesco Albanese; Marco Fantinati; Antonella Rigillo; Francesca Abramo; Raimondo Tornago; Giovanni Tortorella; Maria Massaro; Teresa Bruna Pagano; Julia Buchholz; Giuliano Bettini
Journal:  BMC Vet Res       Date:  2018-10-12       Impact factor: 2.741

2.  A case of an intramural, cavitated feline gastrointestinal eosinophilic sclerosing fibroplasia of the cranial abdomen in a domestic longhair cat.

Authors:  Gordon A Davidson; Samantha S Taylor; Melanie J Dobromylskyj; Francesco Gemignani; Helen Renfrew
Journal:  JFMS Open Rep       Date:  2021-02-23

3.  Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation.

Authors:  Yuki Hasegawa; Kazuha Shosu; Kanako Tsuji; Yumiko Shimoyama; Takako Shimokawa Miyama; Kenji Baba; Masaru Okuda; Kazuhito Itamoto; Masaya Igase; Takuya Mizuno
Journal:  Sci Rep       Date:  2022-09-22       Impact factor: 4.996

4.  Pathological Findings in Gastrointestinal Neoplasms and Polyps in 860 Cats and a Pilot Study on miRNA Analyses.

Authors:  Alexandra Kehl; Katrin Törner; Annemarie Jordan; Mareike Lorenz; Ulrike Schwittlick; David Conrad; Katja Steiger; Benjamin Schusser; Heike Aupperle-Lellbach
Journal:  Vet Sci       Date:  2022-09-03

Review 5.  Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment.

Authors:  Vanessa S Tamlin; Cynthia D K Bottema; Anne E Peaston
Journal:  Vet Med Sci       Date:  2019-10-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.